36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
| Autor: | Gonzalez Martin, A.J., Medioni, J., Harter, P., Cropet, C., Cinieri, S., Denison, U., Fujiwara, H., Vergote, I.B., Bologna, A., Hietanen, S., Rodrigues, M.J., Hanker, L.C., Zamagni, C., Hernando Polo, S., Bello Roufai, D., Bauerschlag, D., You, B., Hillemanns, P., Pujade-Lauraine, E., Ray-Coquard, I.L. |
|---|---|
| Zdroj: | In ESMO Open February 2023 8(1) Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|